Davern Capital Partners, LP
Long book
$364.5M
Q1 2026
Positions
17
Top-10 weight
81%
concentration
Last quarter
+12.2%
SPY +14.8%
Turnover
28%
of book per quarter
Strategy in plain words
auto-generated from filingsDavern Capital Partners, LP is a concentrated fundamental stock-picker, specialised in healthcare (100% of the long book), running a $364.5M US long book across 17 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: PFIZER INC, REGENERON PHARMACEUTICALS, INSMED INC, IONIS PHARMACEUTICALS INC, NATERA INC.
We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q4 2025
+1.7%
Q1 2026
+12.2%
Sector allocation
Healthcare 100%
Long book by quarter
What does Davern Capital own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| PFE PFIZER INC | Healthcare | 1.6M | $44.8M | 12.3% | -22.0% |
| REGN REGENERON PHARMACEUTICALS | Healthcare | 44.8K | $34.6M | 9.5% | -14.5% |
| INSM INSMED INC | Healthcare | 182.6K | $29.9M | 8.2% | New |
| IONS IONIS PHARMACEUTICALS INC | Healthcare | 386.9K | $29.1M | 8.0% | +62.2% |
| NTRA NATERA INC | Healthcare | 144.0K | $28.8M | 7.9% | +83.0% |
| LLY ELI LILLY & CO | Healthcare | 27.3K | $25.1M | 6.9% | +228.4% |
| RPRX ROYALTY PHARMA PLC- CL A | Healthcare | 520.0K | $24.9M | 6.8% | -38.1% |
| ROIV ROIVANT SCIENCES LTD | Healthcare | 873.4K | $24.2M | 6.6% | -15.1% |
| MLYS MINERALYS THERAPEUTICS INC | Healthcare | 447.2K | $12.1M | 3.3% | +112.3% |
| GENB GENERATE BIOMEDICINES INC | Healthcare | 591.8K | $7.4M | 2.0% | New |
| PRCT PROCEPT BIOROBOTICS CORP | Healthcare | 261.2K | $6.5M | 1.8% | New |
| VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 302.5K | $5.9M | 1.6% | +15.6% |